| Company Name: |
3B Pharmachem (Wuhan) International Co.,Ltd.
|
| Tel: |
821-50328103-801 18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:DL-TBOA;DL-threo-β-Benzyloxyasparticacid
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
| Company Name: |
EMMX Biotechnology LLC
|
| Tel: |
888-539-0666 |
| Email: |
info@emmx.com |
| Products Intro: |
Product Name:DL-TBOA
CAS:205309-81-5
Purity:98% HPLC Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
|
| | DL-TBOA Basic information |
| Product Name: | DL-TBOA | | Synonyms: | DL-THREO-BETA-BENZYLOXYASPARTIC ACID;D,L-THREO-B-BENZYLOXYASPARTATE;DL-TBOA;DL-threo-β-Benzyloxyasparticacid;D-Aspartic acid, 3-(phenylmethoxy)-, (3R)-rel-;BYOBCYXURWDEDS-IUCAKERBSA-N;DLTBOA,DL TBOA | | CAS: | 205309-81-5 | | MF: | C11H13NO5 | | MW: | 239.22 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | DL-TBOA Chemical Properties |
| Boiling point | 421.7±45.0 °C(Predicted) | | density | 1.392±0.06 g/cm3(Predicted) | | storage temp. | Desiccate at -20°C | | solubility | <23.92mg/ml in DMSO;insoluble in H2O | | form | solid | | pka | 2.07±0.27(Predicted) | | color | White |
| | DL-TBOA Usage And Synthesis |
| Description | DL-TBOA is an inhibitor of excitatory amino acid transporters (EAATs), with IC50 values of 67 and 5.5 μM for glutamate uptake in COS-1 cells expressing human EAAT1 and EAAT2, respectively. It inhibits inward currents induced by L-aspartate in EAAT4-expressing Xenopus oocytes (Ki = 4.4 μM) and by L-glutamate in EAAT5-expressing oocytes (Ki = 3.2 μM) voltage-clamped at -60 mV. In vivo, DL-TBOA (500 μM, intrahippocampal perfusion) increases extracellular aspartate, glutamate, and alanine levels in rat hippocampus. Intrahippocampal injection of DL-TBOA increases lesion volume in the rat CA1 region in a dose-dependent manner and induces hyperexcitability, wet-dog shakes, salivation, forelimb myoclonus, limbic seizures, and epileptic EEG discharges at a dose of 25 nmol. DL-TBOA (5 and 10 μg, intrathecal) induces antinociception in the second phase of the formalin test in rats when administered 10 minutes prior to formalin. | | Uses | DL-TBOA is a non-transportable excitatory amino acid transporter (EAAT) inhibitor (1). DL-TBOA is a glutamate uptake inhibitor. | | in vitro | dl-tboa inhibited the uptake of [14c]glutamate in cos-1 cells overexpressing the human excitatory amino acid transporter-1 (eaat1) (ki = 42 μm) with almost the same potency as dl-threo-b-hydroxyaspartate (ki = 58 μm). with regard to the human excitatory amino acid transporter-2 (eaat2), the inhibitory effect of dl-tboa (ki = 5.7 μm) was much more potent than that of dihydrokainate (ki = 79 μm), which is well known as a selective blocker of this subtype. [1]. | | in vivo | microdialysis administration of 500 μm dl-tboa into the hippocampus increased 3.4- and nine-fold the extracellular levels of aspartate and glutamate, respectively. upon stereotaxic administration it induced neuronal damage dose-dependently in ca1 and dentate gyrus, and convulsive behavior. electroencephalographic recording showed limbic seizures appearance in the hippocampus after dl-tboa infusion. [2]. | | storage | -20°C (desiccate) | | references | [1] shimamoto k, lebrun b, yasuda-kamatani y, sakaitani m, shigeri y, yumoto n, nakajima t. dl-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. mol pharmacol. 1998 feb;53(2):195-201.
[2] montiel t, camacho a, estrada-sánchez am, massieu l. differential effects of the substrate inhibitor l-trans-pyrrolidine-2,4-dicarboxylate (pdc) and the non-substrate inhibitor dl-threo-beta-benzyloxyaspartate (dl-tboa) of glutamate transporters on neuronal damage and extracellular amino acid levels in rat brain in vivo. neuroscience. 2005;133(3):667-78. |
| | DL-TBOA Preparation Products And Raw materials |
|